Pharmaceutical Trial-A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Our department is currently seeking volunteers that have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF) to participate in a clinical research study of an investigational drug in combination with Pirfenidone.

Key Inclusion Criteria:

  • Adult patients  40 years or older
  • Have a diagnosis of IPF within the previous 5 years from time of screening and confirmed at baseline
  • Would like to or are currently taking Pirfenidone

Key Exclusion Criteria:

  • Lung Transplant expected within 12 months of screening

Please contact Aileen Orpilla by phone at 646-962-5568 or by email at for additional information. Identifier: NCT01872689

IRB Protocol 1305013975

Comments are closed.
%d bloggers like this: